ISBN: 9780521862530

[ED: Hardcover], [PU: Cambridge University Press], An essential update of recent clinical trials in the management of neurological and neuropsychiatric disorders. Published annually, vol… Plus…

[ED: Hardcover], [PU: Cambridge University Press], An essential update of recent clinical trials in the management of neurological and neuropsychiatric disorders. Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of recent trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists. Also available electronically http://www.journals.cambridge.org/jid_PNN. Review quote: "Insights provided in this text concerning clinical trials will allow prescribers to feel more confident regarding the medications they prescribe and the quality research on which clinical efficacy has been established. The research is presented in a detailed yet concise and very readable format. The text provides valuable information regarding neuropsychopharmacology research and treatment. It is a well-written and concise read for scientist-practicioners who want an understanding of the clinical trials that support multiple uses of many commonly prescribed agents. It is a must-read for neurologists, psychiatrists, prescribing psychologists, nurse practicioners, and neuroscientists, particularly those interested in clinical issues. Readers who have an interest in the neurobiology of psychiatric issues may be especially interested in this text. This text would be an excellent complement to pharmacology courses because it provides valuable information concerning the drug development process. In addition, this collection of works may facilitate flexible and creative prescribing practices by evaluating agents in populations and for symptoms other than those for which they were initially developed." Table of contents: Preface J. L. Cummings Introduction to Neurotherapeutics and Neuropharmacology J. L. Cummings 1. Rivastigmine in the treatment of dementia associated with Parkinson's disease: a randomized, double-blind, placebo-controlled study S. Tekin and R. Lane 2. Modafinil for the treatment of fatigue in multiple sclerosis B. Stankoff, C. Lubetzki and M. Clanet 3. Radiotherapy with concurrent and adjuvant temozolomide: a new standard of care for glioblastoma multiform W. P. Mason, R. O. Mirimanoff, and R Stupp 4. Treating migraine attacks ASAP: concept and methodological issues N. J. Wiendels and M. D. Ferrari 5. Early phase trials of minocycline in amyotropic lateral sclerosis P. H. Gordon, J. Choi, D. H. Moore and R. G. Miller 6. Creatine as a potential treatment for amyotrophic lateral sclerosis J. M. Shefner 7. AVP-923 as a novel treatment for pseudobulbar affect ALS L. E. Pope 8. Liquid fluoxetine vs. placebo for repetitive behaviors in childhood autism E. Hollander, E. Swanson, E. Anagnostou, A. Phillips, W. Chaplin and S. Wasserman 9. Testing multiple novel mechanisms for treating schizophrenia in a single trial H. Y. Meltzer 10. Selegiline in the treatment of negative symptoms of schizophrenia A. Lin and A. Bodkin 11. Analysis of the cognitive enhancing effects of modafinil in schizophrenia D. C. Turner and B. J. Sahakian 12. Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatient with schizophrenia or schizoaffective disorder: results of a double-blind, 6-week study, with a 6-month, double-blind, continuation phase G. M. Simpson, A. Loebel, L. Warrington and R. Yang. 184 p. - 254 x 179 mm Versandfertig in 3-5 Tagen, DE, [SC: 0.00], Neuware, gewerbliches Angebot, Offene Rechnung (Vorkasse vorbehalten)<

ISBN: 9780521862530

[ED: Hardcover], [PU: Cambridge University Press], An essential update of recent clinical trials in the management of neurological and neuropsychiatric disorders. Published annually, vol… Plus…

[ED: Hardcover], [PU: Cambridge University Press], An essential update of recent clinical trials in the management of neurological and neuropsychiatric disorders. Published annually, volumes in this series provide readers with updates of recent clinical trial results, impacts of trials on guidelines and evidence-based practice, advances in trial methodologies, and the evolution of biomarkers in trials. The series focuses on trials in neurotherapeutics, including disease-modifying and symptomatic agents for neurological diseases, psychopharmacological management of neurologic and psychiatric illnesses, and non-drug treatments. Each paper is authored by a leader in the area of neurotherapeutics and clinical trials, and the series is guided by an editor-in-chief and editorial board with broad experience in drug development and neuropsychopharmacology. Progress in Neurotherapeutics and Neuropsychopharmacology is an essential update of recent trials in all aspects of the management of neurologic and neuropsychiatric disorders, and will be an invaluable resource for practising neurologists as well as clinical and translational neuroscientists. Also available electronically http://www.journals.cambridge.org/jid_PNN. Review quote: "Insights provided in this text concerning clinical trials will allow prescribers to feel more confident regarding the medications they prescribe and the quality research on which clinical efficacy has been established. The research is presented in a detailed yet concise and very readable format. The text provides valuable information regarding neuropsychopharmacology research and treatment. It is a well-written and concise read for scientist-practicioners who want an understanding of the clinical trials that support multiple uses of many commonly prescribed agents. It is a must-read for neurologists, psychiatrists, prescribing psychologists, nurse practicioners, and neuroscientists, particularly those interested in clinical issues. Readers who have an interest in the neurobiology of psychiatric issues may be especially interested in this text. This text would be an excellent complement to pharmacology courses because it provides valuable information concerning the drug development process. In addition, this collection of works may facilitate flexible and creative prescribing practices by evaluating agents in populations and for symptoms other than those for which they were initially developed." Table of contents: Preface J. L. Cummings Introduction to Neurotherapeutics and Neuropharmacology J. L. Cummings 1. Rivastigmine in the treatment of dementia associated with Parkinson's disease: a randomized, double-blind, placebo-controlled study S. Tekin and R. Lane 2. Modafinil for the treatment of fatigue in multiple sclerosis B. Stankoff, C. Lubetzki and M. Clanet 3. Radiotherapy with concurrent and adjuvant temozolomide: a new standard of care for glioblastoma multiform W. P. Mason, R. O. Mirimanoff, and R Stupp 4. Treating migraine attacks ASAP: concept and methodological issues N. J. Wiendels and M. D. Ferrari 5. Early phase trials of minocycline in amyotropic lateral sclerosis P. H. Gordon, J. Choi, D. H. Moore and R. G. Miller 6. Creatine as a potential treatment for amyotrophic lateral sclerosis J. M. Shefner 7. AVP-923 as a novel treatment for pseudobulbar affect ALS L. E. Pope 8. Liquid fluoxetine vs. placebo for repetitive behaviors in childhood autism E. Hollander, E. Swanson, E. Anagnostou, A. Phillips, W. Chaplin and S. Wasserman 9. Testing multiple novel mechanisms for treating schizophrenia in a single trial H. Y. Meltzer 10. Selegiline in the treatment of negative symptoms of schizophrenia A. Lin and A. Bodkin 11. Analysis of the cognitive enhancing effects of modafinil in schizophrenia D. C. Turner and B. J. Sahakian 12. Efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatient with schizophrenia or schizoaffective disorder: results of a double-blind, 6-week study, with a 6-month, double-blind, continuation phase G. M. Simpson, A. Loebel, L. Warrington and R. Yang. 184 p. - 254 x 179 mm Versandfertig in 3-5 Tagen, DE, [SC: 0.00], Neuware, gewerbliches Angebot, offene Rechnung (Vorkasse vorbehalten)<

2006, ISBN: 9780521862530

An essential update of clinical trials in the management of neurological and neuropsychiatric disorders. Psychology & Psychiatry Psychology & Psychiatry eBook, Cambridge University Press

2006, ISBN: 9780521862530

Buch, Hardcover, [PU: Cambridge University Press], Cambridge University Press, 2006

2006, ISBN: 9780521862530

Hardcover, Buch, [PU: Cambridge University Press]